Effective new drugs will drive CAGR of 13.7% heart failure market

The heart failure market is set to rise from around $3.2 billion in 2015 to $11.8 billion by 2025, representing a compound annual growth rate of 13.7%, new research indicates.

According to research and consulting firm GlobalData’s latest report, the key drivers of this substantial growth, which will occur across the seven major markets of the USA, France, Germany, Italy, Spain, the UK, and Japan, will be the launch of Novartis’ (NOVN: VX) first-in-class drug, Entresto (sacubitril/valsartan), and several acute heart failure add-on therapies, as well as an increase in the global prevalence of chronic heart failure.

Elizabeth Hamson, GlobalData’s analyst covering Cardiovascular and Metabolic Disorders, explains: “Novartis’ Entresto is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNi), which was launched in the US in 2015 and the five European countries in 2016, and is set for release in Japan by 2020. The drug has raised the benchmark for efficacious chronic heart failure therapy, although uptake has been slow.”